诱导TPF后联合同期治疗对比单纯同期治疗在局部晚期头颈鳞癌中的II-III期试验
这项II-III期随机试验纳入414例局部晚期头颈鳞癌患者,比较诱导TPF后联合同期治疗与单纯同期治疗。中位随访44.8个月,诱导组总生存显著更高(HR 0.74;95%CI 0.56-0.97;P=0.031),完全缓解率、无进展生存和局部区域控制也显著更优,且诱导TPF未影响同期治疗依从性。
要点
- 诱导TPF后联合同期治疗较单纯同期治疗显著改善总生存(HR 0.74;95%CI 0.56-0.97;P=0.031)。
- 诱导组完全缓解率(P=0.0028)、无进展生存(P=0.013)和局部区域控制(P=0.036)均显著更高。
- 诱导TPF未影响同期治疗的依从性。
核心结论
- 诱导TPF后联合同期治疗改善了局部晚期头颈鳞癌患者的结局,且未损害同期治疗的依从性。
- 诱导化疗的获益程度可能因后续同期治疗策略不同而有所差异。
研究设计与样本
- II-III期随机试验,纳入局部晚期头颈鳞癌患者,随机接受单纯同期治疗(CCRT为A1组,CET/RT为A2组)或三周期诱导TPF后CCRT(B1组)或CET/RT(B2组)。
- 最终分析414例(诱导组206例,非诱导组208例),排除6例重大方案违背和1例诊断时转移。
- 总生存优效性假设需204例死亡事件,以检测3年OS绝对差异12%(HR 0.675,80%把握度,双侧5%显著性水平)。
主要发现
- 中位随访44.8个月,诱导组总生存显著高于非诱导组(HR 0.74;95%CI 0.56-0.97;P=0.031)。
- 诱导组完全缓解率显著更高(P=0.0028)。
- 诱导组无进展生存显著更高(P=0.013)。
- 诱导组局部区域控制显著更高(P=0.036)。
- 诱导TPF未影响同期治疗的依从性。
关键数值与推荐
- 总生存优效性检验需204例死亡事件,HR 0.675,80%把握度,双侧5%显著性水平。
- 诱导组 vs 非诱导组:HR 0.74(95%CI 0.56-0.97;P=0.031)。
- 完全缓解率组间比较P=0.0028,无进展生存组间比较P=0.013,局部区域控制组间比较P=0.036。
临床怎么用
- 对于局部晚期头颈鳞癌,可考虑三周期诱导TPF后联合同期治疗,以改善生存且不损害同期治疗依从性。
- 诱导化疗的获益程度可能因后续同期治疗策略不同而有所差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platinum-based chemoradiation (CCRT) is the standard treatment for Locally Advanced Head and Neck Squamous-Cell Carcinoma (LAHNSCC). Cetuximab/RT (CET/RT) is an alternative treatment option to CCRT. The efficacy of induction chemotherapy (IC) followed by chemoradiation compared to chemoradiation alone has not been demonstrated in randomized clinical trials. The goals of this phase II-III trial were to assess: (i) the overall survival (OS) of IC versus no-induction (no-IC) and (ii) the Grade 3-4 in-field mucosal toxicity of CCRT versus CET/RT. The present paper focuses on the analysis of efficacy. MATERIALS AND METHODS: Patients with LAHNSCC were randomized to receive concomitant treatment alone [CCRT (Arm A1) or CET/RT (Arm A2)], or three cycles of induction docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1) or followed by CET/RT (Arm B2). The superiority hypothesis of OS comparison of IC versus no-IC (Arms B1 + B2 versus A1 + A2) required 204 deaths to detect an absolute 3-year OS difference of 12% (HR 0.675, with 80% power at two-sided 5% significance level). RESULTS: 414 out of 421 patients were finally analyzed: 206 in the IC and 208 in the no-IC arm. Six patients were excluded because of major violation and one because of metastatic disease at diagnosis. With a median follow-up of 44.8 months, OS was significantly higher in the IC arm (HR 0.74; 95% CI 0.56-0.97; P = 0.031). Complete Responses (P = 0.0028), Progression Free Survival (P = 0.013) and the Loco-regional Control (P = 0.036) were also significantly higher in the IC arm. Compliance to concomitant treatments was not affected by induction TPF. CONCLUSIONS: IC followed by concomitant treatment improved the outcome of patients with LAHNSCC without compromising compliance to the concomitant treatments. The degree of the benefit of IC could be different according to the type of the subsequent concomitant strategy. CLINICAL TRIAL NUMBER: NCT01086826, www.clinicaltrials.gov.
引用
- Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017. PMID: 28911070. doi:10.1093/annonc/mdx299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。